Glioma Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2036 - DelveInsight

DelveInsight's "Glioma Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Glioma, historical and forecasted epidemiology as well as the Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glioma Market Forecast
https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Glioma Market Report:
• The Glioma market size across the 7MM surpassed USD 1 billion in 2025 and is anticipated to expand at a robust CAGR of approximately 15% throughout the forecast period from 2026 to 2036.
• According to DelveInsight's estimates, the United States represented the largest share of the glioma market in 2025, with a market value exceeding USD 600 million. The market is expected to witness further growth, supported by the increasing uptake of innovative and targeted treatment therapies.
• In April 2026, FORE Biotherapeutics announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated Glioma (HGG).
• In March 2026, Glioblastoma multiforme (GBM) is a highly aggressive and invasive brain tumor that develops from the malignant transformation of cells in the brain and spinal cord. Currently, the standard treatment approach involves surgical intervention followed by adjuvant chemotherapy, with temozolomide being the only first-line drug approved by the FDA for GBM management. This study conducted by Shenzhen University aimed to evaluate the efficacy of a novel chloroethyl nitrosourea analog, HJ-03, as a potential treatment for GBM, particularly in overcoming resistance to temozolomide.
• In January 2026, ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company focused on cytokine-based and cellular immunotherapies aimed at restoring immune function, has announced updated Phase 2 data from its QUILT 3.078 trial (NCT06061809). The study is assessing a chemotherapy-free combination immunotherapy approach in patients with second-line recurrent or progressive glioblastoma (GBM), along with individuals treated under single-patient investigational new drug applications (spINDs) spanning first- through third-line settings. QUILT-3.078 specifically enrolled patients experiencing their first recurrence of GBM. Within the spIND group, seven first-line patients remain alive at the time of reporting. Additionally, randomized clinical trials targeting both first-line and second-line or later GBM populations are currently in development.
• In November 2025, GenomOncology announced a strategic collaboration with the Glioblastoma Foundation aimed at advancing genomic testing for glioblastoma, the most aggressive brain cancer in the U.S. Through this partnership, the Foundation's newly launched genomic testing laboratory will incorporate GenomOncology's advanced Pathology Workbench (PWB) platform, significantly speeding up the delivery of genetic test results to patients.
• In June 2025, Diakonos Oncology, a U.S.-based biotechnology firm, has secured $20 million through a private placement of Simple Agreements for Future Equity (SAFE) to accelerate its Phase II glioblastoma trial of dubodencel. The investment will also support the expansion of its clinical portfolio into additional indications, including refractory melanoma. The funding round included participation from new backers such as Baylor College of Medicine and the Brain Tumor Investment Fund, alongside existing investors, including the company's CEO, Mike Wicks.
• In May 2025, According to a press release from Roswell Park Comprehensive Cancer Center, the Phase 2b SURVIVE study (NCT05163080) evaluating SurVaxM, a cancer vaccine, in patients with newly diagnosed glioblastoma will proceed based on interim trial data analysis.
• According to the estimates, the United States recorded the highest Glioma market share, i.e., around 65% of the Glioma market size in 2025.
• Among the EU4 and the UK, Germany (~USD 95 million) has the maximum revenue share in 2025, while Spain has the lowest Glioma market share.
• In 2025, OPTUNE ± TMZ captured the highest Glioma market size in Japan. This combination is expected to generate maximum revenue during the forecast period (2026-2036).
• Conditional and time-limited approval of Daiichi's DELYTACT, an intratumoral oncolytic virus therapy, has opened new doors for other players, such as DNAtrix and Istari Oncology, to develop oncolytic virus therapies, which can prove to be a potential mechanism of action in brain cancer treatment in future.
• Currently, Jazz Pharmaceuticals/Chimerix is the only company in the advanced stage of developing treatments for the H3K27M mutation. Other key players in the early stages of development include Rigel Pharmaceuticals, Aminex Therapeutics, Bexion Pharmaceuticals, OX2 Therapeutics, Neonc Technologies, and others
• According to DelveInsight's estimates, the Glioma Incident Cases in the 7MM were approximately 51, 000 in 2025.
• It has been observed that the incidence of high-grade glioma is higher (~16,700) as compared to low grade glioma (~4,170) in the United States in 2025.
• According to DelveInsight estimates, in the United States, among all the grades, Grade IV accounted for the highest number of incident cases (~70%), followed by Grade II glioma (~15%), while Grade I had the least number of cases (~7%).
• In 2025, among gliomas in other parts of central nervous system in the United States, glioblastoma was the most prevalent in adults than in pediatrics, followed by anaplastic astrocytoma which was also found to be more prevalent in adults than in pediatrics.
• In Japan among gliomas in other parts of the central nervous system, Glioblastoma was found to be more incident in Adults (~2,735) in 2025.
• Key Glioma Companies: Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
• Key Glioma Therapies: Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
• The Glioma epidemiology based on gender analyzed that Glioma is more common in men than in women
• The Glioma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioma pipeline products will significantly revolutionize the Glioma market dynamics.

Glioma Overview
Glioma is a type of tumor that originates from the glial cells, which provide support and protection to nerve cells in the brain and spinal cord. It is one of the most common forms of primary brain tumors and is classified into several subtypes, including astrocytoma, oligodendroglioma, and the highly aggressive glioblastoma. Symptoms vary depending on the tumor's size and location and may include headaches, seizures, cognitive impairment, and neurological deficits. Treatment typically involves a combination of surgery, radiation therapy, chemotherapy, targeted therapies, and, increasingly, immunotherapy. Ongoing research is focused on developing more effective and personalized treatment strategies to improve survival and quality of life for patients with glioma.

Get a Free sample for the Glioma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Glioma Epidemiology
The Glioma epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Glioma Epidemiology Segmentation:
The Glioma market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Incident cases of Glioma
• Grade-specific Incident cases of Glioma
• Age-specific Incident cases of Glioma
• Type-specific Incident cases of Glioma

Download the report to understand which factors are driving Glioma epidemiology trends @ Glioma Epidemiology Forecast
https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioma market or expected to get launched during the study period. The analysis covers Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Glioma Therapies and Key Companies
• Vorasidenib (VORANIGO): Servier Pharmaceuticals
• Dordaviprone (MODEYSO): Jazz Pharmaceuticals
• Regorafenib: Bayer
• AV-GBM-1: Aivita Biomedical
• Enzastaurin: Denovo BioPharma
• Asunercept: Apogenix
• Azeliragon: Cantex
• VXM01: VAXIMM
• MB-101: Mustang Bio
• JIN 001: J INTS BIO
• CT 179: Curtana Pharmaceuticals
• PRT3645: Prelude Therapeutics
• CD200AR L: OX2 Therapeutics
• ADI-PEG 20: Polaris Group
• CM93: Crimson Biopharm
• Berubicin: CNS Pharmaceuticals
• SurVaxM: MimiVax
• BPM31510: Berg, LLC
• ASC40: Ascletis
• Enzastaurin: Denovo Biopharma
• Marizomib: Celgene Corporation

Discover more about therapies set to grab major Glioma market share @ Glioma Treatment Landscape
https://www.delveinsight.com/sample-request/glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Glioma Market Drivers
• Rising Glioma Incidence: Increasing diagnosis of glioma, particularly high-grade glioblastoma, is expanding the patient pool and driving demand for innovative treatment options.
• Advancements in Targeted and Immunotherapies: Growing research into targeted therapies, CAR-T cell therapies, oncolytic viruses, and immune checkpoint inhibitors is creating new growth opportunities in the glioma market.
• Improved Molecular Diagnostics: Wider adoption of biomarker-based testing, including IDH mutation and MGMT methylation status, is enabling personalized treatment approaches and supporting market expansion.
• Increasing Clinical Trial Activity: A robust pipeline of novel therapeutics, coupled with collaborations between biotech companies and academic institutions, is accelerating drug development for glioma.
• Supportive Regulatory Environment: Orphan drug designations, expedited FDA review pathways, and increased funding for rare cancer research are encouraging innovation and commercialization.

Glioma Market Barriers
• Limited Treatment Effectiveness: The aggressive nature of glioma and the presence of the blood-brain barrier continue to limit the efficacy of many therapeutic approaches.
• High Clinical Trial Failure Rates: Complex tumor biology, heterogeneous patient populations, and difficulty achieving meaningful survival benefits contribute to frequent late-stage clinical setbacks.
• High Cost of Advanced Therapies: Emerging personalized treatments, cell therapies, and combination regimens often involve significant costs, creating affordability and reimbursement challenges.
• Delayed Diagnosis and Poor Prognosis: Many patients are diagnosed at advanced stages, resulting in limited treatment options and reducing the overall commercial potential of available therapies.
• Regulatory and Development Challenges: Stringent regulatory requirements, lengthy clinical development timelines, and difficulties in recruiting eligible patients can delay product approvals and market entry.

Scope of the Glioma Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Glioma Companies: Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
• Key Glioma Therapies: Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
• Glioma Therapeutic Assessment: Glioma current marketed and Glioma emerging therapies
• Glioma Market Dynamics: Glioma market drivers and Glioma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Glioma Unmet Needs, KOL's views, Analyst's views, Glioma Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: abhishek@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.